Escolar Documentos
Profissional Documentos
Cultura Documentos
9 - Atualização No Tratamento Das Infecções Por Bactérias Multirresistentes - Clóvis Da Cunha PDF
9 - Atualização No Tratamento Das Infecções Por Bactérias Multirresistentes - Clóvis Da Cunha PDF
choque séptico
Time To Appropriate Antimicrobial Therapy Following Onset of Hypotension (Hours)
Retrospective analysis in 165 global ICUs with a total of 28,150 patients with
severe sepsis or septic shock2
• Survival benefit demonstrated with prompt antibiotics even in patients
with only severe sepsis without shock
Systematic review and meta-analysis questioning the above-stated benefits3
1Kumar A et al. Crit Care Med 2006;34:1589-1596
2Ferrer R et al. Crit Care Med 2014;42:1749-1755
3Sterling SA et al. Crit Care Med 2015;43:1907-1915
Sepsis-3: New Criteria for Sepsis
Sepsis = life-threatening disease
qSOFA: melhor critério de SÉPSIS fora da UTI
“SEPSIS = Life-threatening disease !”
Novos critérios de Sepse:
qSOFA = quick SOFA
E Enterococcus faecium
S Staphylococcus aureus
Acknowledges the growing virulence of C.
C Clostridium difficile difficile
A Acinetobacter baumannii
P Pseudomonas aeruginosa
Carb-R
KPC Pseudo
GVIMS/GGTES/ANVISA, 2016.
“E.S.C.A.P.E.” Bugs: Novos antibióticos
chegando no Brasil em 2017
Meropenem 1g IV 8/8h
Vancomicina em situações
específicas A-I
Suspeita de Resistência:
• Hemocultura
a) MRSA – Vancomicina, + CGP
• Choque
Linezolida, Daptomicina B-III séptico
• Foco pele/tecidos moles
b) VRE - Daptomicina(
c)ESBL – •Carbapenêmico
Inf no local B-III de inserção do
S Staphylococcus aureus
Acknowledges the growing virulence of C.
C Clostridium difficile difficile
A Acinetobacter baumannii
P Pseudomonas aeruginosa
Captures K. pneumoniae, Enterobacter sp., and
E Enterobacteriaceae other resistant species including E. coli and Proteus
sp.
A Acinetobacter baumannii
P Pseudomonas aeruginosa
Captures K. pneumoniae, Enterobacter sp., and
E Enterobacteriaceae other resistant species including E. coli and Proteus
sp.
Vancomicina
Daptomicina
Linezolida
Ceftarolina
IDSA Guidelines for the treatment of MRSA infections Clin Inf Dis 2011;52:13
Vancomicina: quase 6 décadas depois
33
22nd European Congress of Clinical Microbiology and Infectious Diseases
Linezolida (Zyvox) x vancomicina em Infecções
complicadas de Pele e Tecidos moles
92,9%
92,2%
90,4%
89,7%
88,5%
88%
ITT MITT CE ME
p=0,057 p=0,033 p=0,023 p=0,022
Weigelt J et al AAC 2005; 49(6):2260-2266
Vancomicina x Linezolida (Zyvox) em pneumonia
hospitalar por MRSA (Zephyr 2012)
P Pseudomonas aeruginosa
Early termination
Van Nood 2013 NEJM
Redefining ESKAPE…as ESCAPE
E Enterococcus faecium
S Staphylococcus aureus
Acknowledges the growing virulence of C.
C Clostridium difficile difficile
A Acinetobacter baumannii
P Pseudomonas aeruginosa
Pranita DT, Cosgrove SE, Maragakis LS. Combinationation Therapy for Treatment
of Infections with Gram-Negative Bacteria. Clin Microb Reviews 2012;25:450-470.
Tratamento de Pseudomonas: infusão 30min x 4h
APACHE II < 17 APACHE II ≥ 17
N=115 N=79
Mortality in 14 days: 5.2% Mortality in 14 days: 21.5%
Median hospitalization: 18 days Median hospitalization: 22.5 days
CVC, central venous catheter; DOR, doripenem; ERT, ertapenem; IV, intravenous; MER, meropenem
Camargo JF, et al. Antimicrob Agents Chemother. 2015;59:5903-8.
Giamarellou H, et al. Antimicrob Agents Chemother. 2013;57:2388-90.
Spectrum of New Antibiotics
Clinical Cure Rates per Pathogen (cIAI)1 Clinical Cure Rates per Pathogen (cUTI)2
HNSG HC - UFPR
Curitiba - PR Curitiba - PR